Human milk oligosaccharides (hmos)

Overview

HMOs are the third most abundant solid component of breast milk, playing critical roles in gut microbiome establishment, immune development, and pathogen defense. They serve as selective prebiotics for beneficial Bifidobacterium and act as decoy receptors preventing pathogen adhesion. dsm-firmenich produces HMOs via precision fermentation using engineered microorganisms, yielding molecules structurally identical to those in breast milk. The regulatory pathway required jurisdiction-by-jurisdiction safety and efficacy dossiers.

Technical specifications

• Ingredients: precision fermentation-derived human milk oligosaccharides
• Structure: identical to HMOs naturally present in human breast milk
• Production: precision fermentation using engineered microorganisms
• Biological function: selective prebiotic for Bifidobacterium, pathogen decoy receptor, immune system support
• Target market: infant formula manufacturers
• Regulatory: approved in 170+ countries
• Strategic note: retained in dsm-firmenich portfolio following Animal Nutrition divestiture

Technology readiness level

TRL 9 — commercially produced with the broadest regulatory approval footprint of any HMO ingredient supplier.